Why Is MONTE ROSA THERAPEUT (GLUE) Stock Down Today?
By the Top Tier Newswire AI Desk · October 1, 2026 at 10:15 AM ET · reviewed against 6 wire stories
MONTE ROSA THERAPEUT (GLUE) is down -5.03% in the latest session. Our newswire has captured 6 stories on GLUE across 6 sources in the last 36 hours, with AI sentiment reading bullish (avg 64/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why GLUE stock is down today
GLUE stock fell 5.03% to $11.33 in morning trading after opening with a 16.0% gap up from the prior close. The sharp intraday reversal followed positive Phase 1 data for MRT-8102 and a new Buy rating from H.C. Wainwright, but the stock failed to sustain the initial enthusiasm.
What Happened
Monte Rosa Therapeutics (GLUE) announced strong Phase 1 results for MRT-8102, its NEK7-directed molecular glue degrader. The GFORCE-1 study showed 80%, 90% NEK7 degradation and broad reductions in inflammatory biomarkers in subjects with elevated cardiovascular disease risk. The company filed an 8-K on October 1, 2026, disclosing the results and outlining plans for mid-stage trials. H.C. Wainwright initiated coverage with a Buy rating and a $25 price target. Despite these developments, GLUE’s stock declined after hitting a morning high of $14.00, falling to a low of $11.16 before settling at $11.33.
Retail traders and market participants had been closely watching GLUE ahead of the data release. The stock had previously surged over 20% pre-market following the announcement, but the subsequent pullback suggests profit-taking or a reassessment of the data's commercial potential.
What The Data Shows
The stock opened at $13.84, a 16.0% gap up from the prior close of $11.93, but quickly reversed course. Volume of 0.7 million shares was 50% of the 3-month average. The stock is currently trading within its 52-week range of $7.09 to $25.77. Over the past eight sessions, the stock has declined 1.6% from $12.21 to $12.01. Recent insider transactions show three sales totaling $462K in the past 90 days, with no insider buying reported.
What To Watch
Investors will be watching for further details on the upcoming Phase 2 trials and the company’s presentation of MRT-8102 data. Coverage breadth and market reaction to the new H.C. Wainwright rating will also be key.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
GLUE · today's session (5-min) · -5.62% vs prior close · updated 2:14 PM ETAI sentiment, last 36h · averaged over 6 stories · 64/100 bullish
The headlines behind the move
Story flow · 6 stories on the wire, last 36h · hover or tap a dot for the headline
6h agoSeeking AlphaBULLISH 67Product/PR
Monte Rosa plans mid-stage trials for anti-inflammatory agent after positive Phase 1 data
Monte Rosa Therapeutics (GLUE) stock gains as the company plans Phase 2 trials for anti-inflammatory agent MRT-8102 after strong Phase 1 results. Read more here.
Monte Rosa’s MRT-8102 Phase 1 data show 80%–90% NEK7 degradation and broad inflammatory marker reductions
October 1, 2026
Monte Rosa Therapeutics (GLUE) reported positive Phase 1 GFORCE-1 data for MRT-8102, citing robust and sustained NEK7 degradation of approximately 80%–90% across tested doses and broad reductions in ASCVD-related biomarkers. The company also reported a favorable safety profile with no serious adverse events and TEAE rates similar to placebo, and outlined planned Phase 2 studies in coronary artery disease, gout, and hidradenitis suppurativa.
8h agoBusiness InsiderBULLISH 73Product/PR
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized multiple atherosclerotic...
8h agoThe FlyBULLISH 61Analyst
Monte Rosa Therapeutics initiated with a Buy at H.C. Wainwright
23h agoGlobeNewswireBULLISH 59Product/PR
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →